Liver cancer

There are 345 papers on liver cancer in aging research: 5 trials and 161 observational studies in people, 38 in animals, 7 in cells, 78 reviews. The newest story, Nov 16, 2026: “Low predicted muscle mass showed no strong link to cancer risk”.

Disease

345 papers study it94 more mention it107 findings

31 new papers in 30 daysSee all 439 papers on liver cancer

At a glance

Human cohorts link accelerated biological aging and frailty with higher liver cancer risk, while immune aging increases liver cancer in a humanized mouse model. Caloric restriction prevents liver cancer in diethylnitrosamine-treated male mice and steatosis-driven animal models. A human trial reports lower liver cancer risk with hepatitis B vaccination.

107 findings in 78 papers from 2010 to 2026, 32 of them since April 2026

“HRs for CEE plus MPA vs placebo elevated in the post-intervention phase (HR, 2.11; 95% CI, 1.06–4.18”
Menopausal hormone therapy and primary liver cancer: long-term follow-up of the women's health initiative randomized trialsBritish journal of cancer2026doi:10.1038/s41416-026-03621-9
  • Human trial5
  • Humans161
  • Animals38
  • Cells7
  • In silico53

Interventions

16

Caloric restriction

downin animals1downin mice1

2 studies
  1. Caloric restriction prevents liver cancer in diethylnitrosamine-treated mice.

    “CR prevented hepatic tumor formation.”

    Animalsin diethylnitrosamine-treated miceliver49 weeksmales

    Caloric Restriction Prevents Carcinogen-Initiated Liver Tumorigenesis in Mice

    Cancer prevention research (Philadelphia, Pa.)

  2. Caloric restriction prevents liver cancer in steatosis-driven liver cancer models (complete inhibition).

    “Caloric restriction inhibits hepatosteatosis, reduces Wnt/β-catenin activation and blocks the expansion of TICs leading to complete inhibition of tumorigenesis”

    Animalsin steatosis-driven liver cancer models

    Wnt/β-catenin activation and macrophage induction during liver cancer development following steatosis

    Oncogene

More on Caloric restriction

Conjugated equine estrogens + medroxyprogesterone acetate

no changein humans1HR 1.63

1 study
  1. Conjugated equine estrogens + medroxyprogesterone acetate showed no clear effect on liver cancer in humans (HR 1.63; 95% CI, 0.91–2.92).

    “Over cumulative follow-up, liver cancer incidence did not differ significantly between the CEE plus MPA and placebo group”

    Human trialn = 16,608

    Hormone trials found no clear liver cancer effect in women

    British journal of cancer

  2. Conjugated equine estrogens + medroxyprogesterone acetate showed no clear effect on liver cancer in humans (HR 1.63; 95% CI, 0.91-2.92).

    “CEE plus MPA vs placebo (30 vs 18 cancers; HR 1.63; 95% CI, 0.91-2.92)”

    Human trial0.625 mg/d + 2.5 mg/dnearly 24 yearsfemalesn = 16,608

    Hormone trials found no clear liver cancer effect in women

    British journal of cancer

More on Conjugated equine estrogens + medroxyprogesterone acetate

Conjugated equine estrogens

no changein humans1HR 0.75

1 study
  1. Conjugated equine estrogens showed no clear effect on liver cancer in humans (HR, 0.75; 95% CI, 0.34–1.63).

    “Through cumulative follow-up, CEE-alone was not associated with liver cancer incidence (11 cancers [0.012% per year] vs 15 cases [0.016% per year]); HR, 0.75; 95% CI, 0.34–1.63).”

    Human trialn = 10,739

    Hormone trials found no clear liver cancer effect in women

    British journal of cancer

  2. Conjugated equine estrogens showed no clear effect on liver cancer in humans (HR 0.75; 95% CI, 0.34-1.63).

    “neither CEE-alone nor CEE plus MPA influenced liver cancer development (CEE-alone vs placebo (11 vs 15 cancers; hazard ratio [HR] 0.75; 95% CI, 0.34-1.63”

    Human trial0.625 mg/dnearly 24 yearsfemalesn = 10,739

    Hormone trials found no clear liver cancer effect in women

    British journal of cancer

More on Conjugated equine estrogens

Trihalomethanes

no changein humans1

1 study
  1. Trihalomethanes were not clearly linked with liver cancer in humans (residential drinking water exposure).

    “Residential drinking water THM exposure was not associated with liver cancer.”

    Humansresidential drinking water exposureliverlong-term

    Long-term exposure to trihalomethanes in drinking water and risk of liver and kidney cancer: a population-based cohort study

    Environment international

More on Trihalomethanes

Opium

no changein humans1

1 study
  1. Opium was not clearly linked with liver cancer in humans.

    “Opium was not associated with liver cancer.”

    Humans

    Tobacco and opium use and risk of liver and colorectal cancer mortality: Analysis of the Golestan Cohort Study (GCS)

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

More on Opium

Periodontal disease

no changein humans1HR 0.99

1 study
  1. Periodontal disease was not clearly linked with liver cancer in pooled analysis of 3 cohorts (HR 0.99, 95% CI 0.67-1.47).

    “periodontal disease (HR = 0.99; 95% CI, 0.67-1.47) and complete tooth loss (HR = 1.29; 95% CI, 0.71-2.35) were not associated with liver cancer risk”

    Humansin pooled analysis of 3 cohortsn = 230,915

    Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

More on Periodontal disease

Nicotinamide

downin mice1

1 study
  1. Nicotinamide decreases liver cancer in stressed mice.

    “nicotinamide administration, recovers CD8+ T cell function in stressed mice and reduces liver cancer progression.”

    Animalsin stressed miceliver

    Chronic stress drives liver cancer by impairing the hepatic kynurenine pathway and immune surveillance

    Nature metabolism

More on Nicotinamide

Artificially sweetened beverages

no changein humans1HR 1.17

1 study
  1. Artificially sweetened beverages were not clearly linked with liver cancer in humans (Postmenopausal women; intake measured at 3-year follow-up) (Adjusted HR 1.17 (95% CI 0.70–1.94); P = .55).

    “individuals who consumed 1 or more artificially sweetened beverages per day did not have significantly increased incidence of liver cancer”

    HumansPostmenopausal women; intake measured at 3-year follow-up1 or more servings per day versus 3 or fewer servings per monthfemales

    Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Liver Cancer and Chronic Liver Disease Mortality

    JAMA

More on Artificially sweetened beverages

Polyunsaturated fatty acids

no changein humans1HR 1

1 study
  1. Polyunsaturated fatty acids were not clearly linked with liver cancer in humans (1-SD increment) (HR 1.00 (95% CI 0.89-1.13)).

    “1.00 (0.89-1.13) for polyunsaturated fat”

    Humans1-SD incrementliver1996-2000 to the end of 2016femalesn = 72,704

    Dietary fat intake and liver cancer risk: A prospective cohort study in Chinese women

    Cancer biology & medicine

More on Polyunsaturated fatty acids

Monounsaturated fatty acids

no changein humans1HR 1.06

1 study
  1. Monounsaturated fatty acids were not clearly linked with liver cancer in humans (1-SD increment) (HR 1.06 (95% CI 0.93-1.21)).

    “1.06 (0.93-1.21) for monounsaturated fat”

    Humans1-SD incrementliver1996-2000 to the end of 2016femalesn = 72,704

    Dietary fat intake and liver cancer risk: A prospective cohort study in Chinese women

    Cancer biology & medicine

More on Monounsaturated fatty acids

All 16

Upstream

8

Jiangsu Province cancer registry data (2010-2021)

downin humans1

1 study
  1. Jiangsu Province cancer registry data (2010-2021) is linked with lower liver cancer in humans.

    “declined for esophageal, gastric, and liver cancer”

    Humans2010-2021

    Trends and future burden of major digestive system cancers in Jiangsu Province, China, 2010-2030

    Frontiers in oncology

Metabolic dysfunction-associated steatotic liver disease

no changein humans1

1 study
  1. Metabolic dysfunction-associated steatotic liver disease was not clearly linked with liver cancer in individuals with chronic HBV infection.

    “MASLD was not linked to primary liver cancer”

    Humansin individuals with chronic HBV infectionmedian follow-up: 13.7 years

    Concurrent MASLD and Long-term Outcomes in HBV-infected Individuals: A Population-based Cohort Study

    Biomedical and environmental sciences : BES

More on Metabolic dysfunction-associated steatotic liver disease

OMA1

downin mice1

1 study
  1. OMA1 protects against liver cancer in mice (deletion of OMA1).

    “deletion of the mitochondrial stress integrator OMA1 increases hepatic primary tumor incidence”

    Animalsdeletion of OMA1liver

    Liver tumors were more common in mice lacking a stress protein

    The EMBO journal

More on OMA1

Free testosterone

no changein humans1

1 study
  1. Free testosterone was not clearly linked with liver cancer in humans.

    “free testosterone was inversely associated with primary liver cancer in males (HR2: 0.42, 0.32-0.55) and no association was observed in females.”

    HumansMedian follow-up of 11.8 yearsfemales

    Total testosterone, sex hormone-binding globulin, and free testosterone concentrations and risk of primary liver cancer: A prospective analysis of 200,000 men and 180,000 postmenopausal women

    International journal of cancer

More on Free testosterone

Immune aging

upin mice1

1 study
  1. Immune aging increases liver cancer in mice (liver cancer humanized mouse model).

    “Finally, we showed faster liver tumor growth in aging than younger humanized mice”

    Animalsliver cancer humanized mouse model

    Towards a better preclinical cancer model - human immune aging in humanized mice

    Immunity & ageing : I & A

Telomere length

no changein humans1

1 study
  1. Telomere length was not clearly linked with liver cancer in humans (Mendelian randomization analysis).

    “There was no direct link between telomere length and fatty liver, hepatic fibrosis, or liver cancer.”

    HumansMendelian randomization analysis

    Causal relationships between telomere length and liver disease: a Mendelian randomization study

    Frontiers in genetics

More on Telomere length

ALTRE

downin mice1

1 study
  1. ALTRE prevents liver cancer in mice (Treg-specific deletion).

    “Treg-specific deletion of Altre did not affect Treg homeostasis and function in young mice but caused Treg metabolic dysfunction, inflammatory liver microenvironment, liver fibrosis and liver cancer in aged mice.”

    AnimalsTreg-specific deletionliver

    A Treg-specific long noncoding RNA maintains immune-metabolic homeostasis in aging liver

    Nature aging

More on ALTRE

FBP1

downin mice1

1 study
  1. FBP1 protects against liver cancer in mice (shown by hepatocyte-specific Fbp1 deletion).

    “genetic evidence for FBP1 as a metabolic tumour suppressor in liver cancer”

    Animalsshown by hepatocyte-specific Fbp1 deletionliver

    FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome

    Nature cell biology

More on FBP1

Associations

70

Statins

downin humans3

3 studies
  1. Statins are linked with a lower risk of liver cancer in humans (aHR 0.52 (95% CI 0.44-0.61)).

    “Site-specific analyses demonstrated reduced risk of liver cancer (aHR, 0.52; 95% CI, 0.44-0.61;”

    Humans≥6 months

    Statin Use and Site-Specific Cancer Risk: A Nationwide Cohort Study Using Korean Health Insurance Data

    Journal of lipid and atherosclerosis

  2. Statins are linked with a lower risk of liver cancer in humans (steatotic liver disease (fatty liver index ≥ 30)) (SHR, 0.63; 95% CI, 0.52–0.76).

    “primary liver cancer (SHR, 0.63; 95% CI, 0.52–0.76)”

    Humanssteatotic liver disease (fatty liver index ≥ 30)≥ 365 cDDDmedian 9 yearsn = 125,926

    Statin use and the risk of liver-related events in older adults with steatotic liver disease

    Scientific reports

  3. Statins lower the risk of liver cancer in humans (cumulative statin exposure, dose-dependent association).

    “a large Veterans Affairs cohort demonstrating a dose-dependent association between cumulative statin exposure and lower primary liver cancer risk in MASLD”

    Reviewcumulative statin exposure, dose-dependent association

    Beyond cardiovascular protection: a conceptual and translational review of the hepato-specific mechanisms of statins in metabolic dysfunction-associated steatotic liver disease (MASLD)

    Frontiers in pharmacology

More on Statins

GLP-1 receptor agonists

downin humans2upin humans1HR 0.47–0.74

3 studies
  1. GLP-1 receptor agonists are linked with a higher risk of liver cancer in humans (3.9% vs. 3.4%; aHR 1.36 (95% CI 1.20-1.54)).

    “Primary liver cancer occurred more frequently in GLP-1 users (3.9% vs. 3.4%, aHR 1.36, 95% CI 1.20-1.54; p < 0.001).”

    Humanscompared with bariatric surgery in patients with obesity and cirrhosis, propensity-matched cohortn = 14,240

    Comparative Outcomes of GLP-1 Therapy vs. Bariatric Surgery in Patients with Cirrhosis

    Obesity surgery

  2. GLP-1 receptor agonists are linked with a lower risk of liver cancer in humans (type 2 diabetes, compared to insulin) (HR 0.47, 95% CI 0.27-0.82).

    “Compared to insulin, GLP-1RA medications were associated with a significantly lower risk of liver cancer (HR: 0.47, 95% CI: 0.27-0.82)”

    Humanstype 2 diabetes, compared to insulinn = 106,088

    Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists

    Journal of general internal medicine

  3. GLP-1 receptor agonists lower the risk of liver cancer in humans (subgroup analysis) (HR: 0.74; 95% CI: 0.62-0.88).

    “liver cancer (HR: 0.74; 95% CI: 0.62-0.88).”

    Reviewsubgroup analysis

    Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies

    Frontiers in pharmacology

More on GLP-1 receptor agonists

Hepatitis B vaccine

downin humans2HR 0.28

2 studies
  1. Hepatitis B vaccine lowers the risk of liver cancer in humans (HR 0.28, 95% CI 0.11-0.70, P = 0.007).

    “The incidence rate of liver cancer was significantly lower in the vaccinated group than in the control group [HR, 0.28; 95% confidence interval (CI) 0.11-0.70, P = 0.007].”

    Human trialliver37 years

    Long term outcome of prevention of liver cancer by hepatitis B vaccine: Results from an RCT with 37 years

    Cancer letters

  2. Hepatitis B vaccine lowers the risk of liver cancer in humans.

    “hepatitis B vaccination lowers the risk of chronic infection and liver cancer”

    Review

    Cancer Prevention Must Begin Earlier: A Life-Course Perspective

    Developmental medico-life-sciences

More on Hepatitis B vaccine

Diabetes mellitus

upin humans2

2 studies
  1. Diabetes mellitus is linked with a higher risk of liver cancer in humans (retrospective cohort using EHRs) (1275 developed liver cancer during follow-up (median 6.25 y)).

    “Of the 190,971 patients included, 1275 developed liver cancer during follow-up (median 6.25 y).”

    Humansretrospective cohort using EHRsn = 190,971

    Comparison of Risk Factors, Their Interaction Patterns, and Scoring Systems for Liver Cancer Between Patients With and Those Without Diabetes: Retrospective Cohort Study Using Electronic Health Records and Tree-Structured Algorithms

    JMIR medical informatics

  2. Diabetes mellitus is associated with liver cancer in humans (Diabetes diagnosed at >40 years).

    “with a prominently increased risk of liver cancer since the diagnosis age of >40 years.”

    HumansDiabetes diagnosed at >40 years

    Association between diabetes at different diagnostic ages and risk of cancer incidence and mortality: a cohort study

    Frontiers in endocrinology

More on Diabetes mellitus

Alcohol

upin humans1downin humans1

2 studies
  1. Alcohol is linked with a higher risk of liver cancer in humans.

    “From 1990 to 2021, the burden of liver cancer attributed to alcohol consumption increased significantly”

    Humans

    Global, regional, and national liver cancer attributable to smoking and alcohol use burden, 1990-2021: analysis for the global burden of disease 2021 study

    BMC public health

  2. Alcohol is associated with liver cancer in humans.

    “However, the burden attributable to alcohol use and smoking has shown a downward trend in recent years.”

    Humans

    Burden of Liver Cancer Attributable to Five Risk Factors by Specific Etiologies in 204 Countries and Territories

    Research SquarePreprint

More on Alcohol

Diabetes risk reduction diet

downin humans2HR 0.69

2 studies
  1. Diabetes risk reduction diet is linked with a lower risk of liver cancer in men who ever smoked (HR per SD 0.82, 95% CI 0.75-0.98).

    “associations of mDRRD (HR per SD = 0.82, 95 % CI: 0.75-0.98) and mWCRF/AICR (HR per SD = 0.83, 95 % CI: 0.74-0.99) on liver cancer risk were significant in men who ever smoked”

    Humansin men who ever smokedmales

    Adherence to dietary guidelines and liver cancer risk: Results from two prospective cohort studies

    Clinical nutrition ESPEN

  2. Diabetes risk reduction diet is associated with liver cancer in humans (Postmenopausal women) (HR 0.69, 95% CI 0.49–0.97; tertile 3 versus tertile 1).

    “A higher DRRD score was significantly associated with a reduced risk of developing liver cancer”

    HumansPostmenopausal womenHighest versus lowest DRRD score tertileMedian follow-up of 22.0 yearsfemalesn = 98,786

    Diabetes risk reduction diet and risk of liver cancer and chronic liver disease mortality: A prospective cohort study

    Journal of internal medicine

More on Diabetes risk reduction diet

Magnesium

downin humans2HR 0.65

2 studies
  1. Magnesium is linked with a lower risk of liver cancer in humans (HR 0.65 (95% CI 0.48–0.87), highest vs lowest quartile).

    “intakes in the highest compared with lowest quartile associated with 35% lower risk (HR: 0.65; 95% CI: 0.48, 0.87)”

    Humanshighest vs lowest intake quartilen = 536,359

    Magnesium intake is associated with a reduced risk of incident liver cancer, based on an analysis of the NIH-American Association of Retired Persons (NIH-AARP) Diet and Health Study prospective cohort

    The American journal of clinical nutrition

  2. Magnesium is linked with a lower risk of liver cancer in humans (highest vs lowest tertile of total intake (diet and supplements)) (HR tertile 3 vs 1: 0.44 (95% CI 0.24, 0.80); ptrend = 0.0065).

    “Total (diet + supplements) magnesium intake was found to be inversely associated with risks of PLC incidence”

    Humanshighest vs lowest tertile of total intake (diet and supplements)diet and supplements

    Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

    International journal of cancer

More on Magnesium

Conjugated equine estrogens + medroxyprogesterone acetate

upin humans1HR 2.11–4.3

1 study
  1. Conjugated equine estrogens + medroxyprogesterone acetate raises the risk of liver cancer in humans (post-intervention phase) (HR, 2.11; 95% CI, 1.06–4.18).

    “HRs for CEE plus MPA vs placebo elevated in the post-intervention phase (HR, 2.11; 95% CI, 1.06–4.18”

    Human trialpost-intervention phasen = 16,608

    Hormone trials found no clear liver cancer effect in women

    British journal of cancer

  2. Conjugated equine estrogens + medroxyprogesterone acetate raises the risk of liver cancer in humans (prior oral contraceptive users) (HR 4.30, 95% CI, 1.46-12.72).

    “prior oral contraceptive users (HR 4.30, 95% CI, 1.46-12.72; P-interaction 0.01)”

    Human trialprior oral contraceptive users0.625 mg/d + 2.5 mg/dnearly 24 yearsfemales

    Hormone trials found no clear liver cancer effect in women

    British journal of cancer

More on Conjugated equine estrogens + medroxyprogesterone acetate

Thrombocytopenia

upin humans1

1 study
  1. Thrombocytopenia is associated with liver cancer in humans (UK individuals with isolated thrombocytopenia).

    “The relative risk of non-malignant liver disease, liver cancer, and death from liver disease was increased in UK individuals with isolated thrombocytopenia.”

    HumansUK individuals with isolated thrombocytopenia

    Mildly low platelets alone linked to modest blood disease risk

    BMJ medicine

More on Thrombocytopenia

Sarcopenia index polygenic risk score

downin humans1OR 0.98

1 study
  1. Sarcopenia index polygenic risk score is associated with liver cancer in humans (OR 0.98, 95% CI 0.96–1.00; p = 0.037).

    “liver cancer (OR = 0.98 [95% CI 0.96–1.00], p = 0.037)”

    Humansn = 389,804

    Muscle-related genetic score linked to lower liver disease odds

    Biomedicines

More on Sarcopenia index polygenic risk score

All 70

Trial sponsors

Funding

42 grants since 2016

National Cancer Institute$46MJapan Society for the Promotion of Science¥57.5MNational Institute on Aging$14.2M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Biological age acceleration and frailty are linked with higher liver cancer risk in human cohorts; immune aging increases liver cancer in a humanized mouse model. A human trial reports that hepatitis B vaccination lowers risk. Observational studies link statins with lower risk, while polyunsaturated fatty acids show either a link with lower risk or no clear link.

  2. Summary rewritten as its findings changed.

    As it read before

    Biological age acceleration and frailty are linked with higher liver cancer risk in human cohorts, while statin use is linked with lower risk. A human trial reports lower risk after hepatitis B vaccination. Dietary associations vary: polyunsaturated fatty acids are linked with lower risk in a cohort but show no clear link in another cohort of women.

  3. Summary rewritten as its findings changed.

    As it read before

    A human study associates statin use for at least six months with lower liver cancer risk; another links microplastics to higher risk.

  4. Summary written from the findings.

Latest

Dec 2025: 10Jan 2026: 28Feb 2026: 24Mar 2026: 28Apr 2026: 5May 2026: 4Jun 2026: 15Jul 2026: 10Aug 2026: 23Sep 2026: 23Oct 2026: 24Nov 2026: 9203 papers in 12 months
Cancer Prevention Research

Low predicted muscle mass showed no strong link to cancer risk

Men with low predicted muscle mass had a hazard ratio of 1.04 for overall cancer versus other men—a small difference in relative risk.Men with low predicted muscle mass had a hazard ratio of 1.04 for overall cancer versus other men—a small difference in relative risk.

Cohort · 4,441,403 peopleCancer
BMJ Medicine

Mildly low platelets alone linked to modest blood disease risk

Ten-year blood disease risks were at most 4% in UK adults and 7% in Denmark, versus at most 2% with normal platelet and hemoglobin levels.Ten-year blood disease risks were at most 4% in UK adults and 7% in Denmark, versus at most 2% with normal platelet and hemoglobin levels.

Cohort · 485,103 peopleHematologic disease
Biomedicines

Muscle-related genetic score linked to lower liver disease odds

Higher genetic scores were linked to lower odds of nonalcoholic fatty liver disease, with an odds ratio of 0.97 compared with lower scores.Higher genetic scores were linked to lower odds of nonalcoholic fatty liver disease, with an odds ratio of 0.97 compared with lower scores.

Genetic association · 389,804 peopleLiver disease

See all 439 papers on liver cancer